[Federal Register Volume 89, Number 204 (Tuesday, October 22, 2024)]
[Rules and Regulations]
[Pages 84281-84286]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-24083]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
21 CFR Part 1308
[Docket No. DEA-1142]
Schedules of Controlled Substances: Placement of Ethylphenidate
in Schedule I
AGENCY: Drug Enforcement Administration, Department of Justice.
ACTION: Final rule.
-----------------------------------------------------------------------
SUMMARY: With the issuance of this final rule, the Drug Enforcement
Administration places ethylphenidate (chemical name: ethyl 2-phenyl-2-
(piperidin-2-yl)acetate), including its salts, isomers, and salts of
isomers, in schedule I of the Controlled Substances Act. This action is
being taken, in part, to enable the United States to meet its
obligations under the 1971 Convention on Psychotropic Substances. When
finalized, this action would impose the regulatory controls and
administrative, civil, and criminal sanctions applicable to schedule I
controlled substances on persons who handle (manufacture, distribute,
reverse distribute, import,
[[Page 84282]]
export, engage in research, conduct instructional activities or
chemical analysis with, or possess) or propose to handle
ethylphenidate.
DATES: Effective date: November 21, 2024.
FOR FURTHER INFORMATION CONTACT: Dr. Terrence L. Boos, Drug and
Chemical Evaluation Section, Diversion Control Division, Drug
Enforcement Administration; Telephone: (571) 362-3249.
SUPPLEMENTARY INFORMATION:
Legal Authority
The United States is a party to the 1971 United Nations Convention
on Psychotropic Substances (1971 Convention), Feb. 21, 1971, 32 U.S.T.
543, 1019 U.N.T.S. 175, as amended. Procedures respecting changes in
drug schedules under the 1971 Convention are governed domestically by
21 U.S.C. 811(d)(2)-(4). When the United States receives notification
of a scheduling decision pursuant to Article 2 of the 1971 Convention
indicating that a drug or other substance has been added to a schedule
specified in the notification, the Secretary of Health and Human
Services (Secretary),\1\ after consultation with the Attorney General,
shall first determine whether existing legal controls under subchapter
I of the Controlled Substances Act (CSA) and the Federal Food, Drug,
and Cosmetic Act meet the requirements of the schedule specified in the
notification with respect to the specific drug or substance.\2\ In the
event that the Secretary did not so consult with the Attorney General,
and the Attorney General did not issue a temporary order, as provided
under 21 U.S.C. 811(d)(4), the procedures for permanent scheduling set
forth in 21 U.S.C. 811(a) and (b) control.
---------------------------------------------------------------------------
\1\ As discussed in a memorandum of understanding entered into
by the FDA and the National Institute on Drug Abuse (NIDA), FDA acts
as the lead agency within HHS in carrying out the Secretary's
scheduling responsibilities under the CSA, with the concurrence of
NIDA. 50 FR 9518 (Mar. 8, 1985). The Secretary has delegated to the
Assistant Secretary for Health of HHS the authority to make domestic
drug scheduling recommendations. Comprehensive Drug Abuse Prevention
and Control Act of 1970, Public Law 91-513, As Amended; Delegation
of Authority, 58 FR 35460 (July 1, 1993).
\2\ 21 U.S.C. 811(d)(3).
---------------------------------------------------------------------------
Pursuant to 21 U.S.C. 811(a)(1) and (2), the Attorney General (as
delegated to the Administrator of the Drug Enforcement Administration
(DEA) pursuant to 28 CFR 0.100) may, by rule, and upon the
recommendation of the Secretary, add to such a schedule or transfer
between such schedules any drug or other substance, if he finds that
such drug or other substance has a potential for abuse, and makes with
respect to such drug or other substance the findings prescribed by 21
U.S.C. 812(b) for the schedule in which such drug or other substance is
to be placed.
Background
Ethylphenidate is a central nervous system stimulant and shares
structural and pharmacological similarities with other schedule II
stimulants, such as methylphenidate. On April 21, 2017, the Secretary-
General of the United Nations advised the Secretary of State of the
United States that, during its 60th session on March 16, 2017, the
Commission on Narcotic Drugs (CND) voted to place ethyl 2-phenyl-2-
(piperidin-2-yl)acetate (ethylphenidate) in Schedule II of the 1971
Convention (CND Dec/60/7). Because the procedures in 21 U.S.C.
811(d)(3) and (4) for consultation and issuance of a temporary order
for ethylphenidate were not followed, as discussed above in the legal
authority section, DEA is utilizing the procedures for permanent
scheduling set forth in 21 U.S.C. 811(a) and (b) to control
ethylphenidate. Permanently scheduling ethylphenidate satisfies the
United States' international obligations.
DEA and HHS Eight Factor Analyses
In a letter dated October 26, 2020, in accordance with 21 U.S.C.
811(b), and in response to DEA's April 3, 2019 request, HHS provided to
DEA a scientific and medical evaluation and scheduling recommendation
for ethylphenidate. DEA reviewed the scientific and medical evaluation
and scheduling recommendation for schedule I placement provided by HHS,
and all other relevant data, pursuant to 21 U.S.C. 811(b) and (c), and
conducted its own analysis under the eight factors stipulated in 21
U.S.C. 811(c). DEA found, under 21 U.S.C. 811(b)(1), that this
substance warrants control in schedule I. Both DEA and HHS Eight-Factor
analyses are available in their entirety under the tab Supporting
Documents of the public docket for this action at https://www.regulations.gov under docket number DEA-1142.
Notice of Proposed Rulemaking To Schedule Ethylphenidate
On September 22, 2023, DEA published a notice of proposed
rulemaking (NPRM) to permanently control ethylphenidate in schedule
I.\3\ Specifically, DEA proposed to add ethylphenidate to the list of
stimulant substances under 21 CFR 1308.11(f). The NPRM provided an
opportunity for interested persons to file a request for hearing in
accordance with DEA regulations on or before October 23, 2023. DEA did
not receive any requests for such a hearing. The NPRM also provided an
opportunity for interested persons to submit comments on or before
November 21, 2023.
---------------------------------------------------------------------------
\3\ Schedules of Controlled Substances: Placement of
Ethylphenidate in Schedule I, 88 FR 65330 (Sept. 22, 2023).
---------------------------------------------------------------------------
Comments Received
DEA received ten comments in response to the notice of proposed
rulemaking for the placement of ethylphenidate into schedule I of the
CSA. The submissions were from individuals or anonymous commenters.
Five commenters provided support for the notice of proposed rulemaking,
four commenters were against the placement of ethylphenidate in
schedule I of the CSA, and one commenter expressed statements that were
neither for nor against the proposed rule.
DEA received five comments in support of the placement of
ethylphenidate in schedule I.
DEA Response: DEA appreciates these comments in support of this
rulemaking.
DEA received four comments against the placement of ethylphenidate
in schedule I of the CSA. The following are DEA's responses to the
individual comments against the proposed rulemaking.
DEA received a comment asserting that methylphenidate is already
controlled under schedule II of the CSA, thus, ethylphenidate is
considered controlled under the Controlled Substances Analogue Act due
to their similarities. This commenter concluded that the government
should not dictate what researchers may study for legitimate scientific
use.
DEA Response: DEA appreciates this comment and would like to
provide further clarification regarding the control of ethylphenidate.
Ethylphenidate has been placed under international control. In order to
comply with treaty obligations, DEA must place ethylphenidate under the
most appropriate schedule, taking into consideration all appropriate
scientific data. This is true even if this substance could be treated
under the Controlled Substances Analogue provision. Additionally, as
set forth in the NPRM, ethylphenidate has no currently accepted medical
use in treatment in the United States. Therefore, ethylphenidate must
be placed in schedule I of the CSA along with other substances which
have no currently accepted medical use, lack
[[Page 84283]]
accepted safety for use under medical supervision, and possess a high
potential for abuse. With respect to scientific research, the placement
of substances in schedule I of the CSA does not preclude academic
research on these substances. DEA registrants wishing to conduct
research on schedule I substances may apply for permission to do so
through the schedule I researcher registration program.\4\
---------------------------------------------------------------------------
\4\ https://apps.deadiversion.usdoj.gov/webforms2/spring/main?execution=e1s2.
---------------------------------------------------------------------------
DEA received a comment comparing ethylphenidate to methylphenidate.
The commenter questioned the reasonable nature of placing
ethylphenidate in schedule I of the CSA considering it is a weaker
substance when compared to methylphenidate, a schedule II substance.
DEA Response: DEA appreciates this comment and asserts the
following: Ethylphenidate belongs to the stimulant class of drugs and
possesses abuse liability similar to that of methylphenidate; however,
unlike methylphenidate, ethylphenidate has no currently accepted
medical use in treatment in the United States. A qualification for
placing substances in schedules II thorough IV of the CSA is that they
must have a currently accepted medical use in treatment in the United
States. Thus, DEA asserts that the placement of ethylphenidate in
schedule I of the CSA is warranted.
DEA received a comment with statements against the NPRM placing
ethylphenidate in schedule I of the CSA. The commenter stated that, in
the NPRM, DEA failed to provide a reason for the placement of
ethylphenidate in a more restrictive schedule (here, schedule I) than
methylphenidate, considering the two drugs share significant
pharmacological similarities and are considered analogues of one
another. The commenter further stated that because ethylphenidate is an
analog of methylphenidate, it may be possible in the future for
ethylphenidate to be marketed as an alternative to methylphenidate. In
particular, the commenter stated the placement of ethylphenidate in
schedule I of the CSA would completely hamper future legitimate
research regarding its medical efficacy. Thus, the commenter states, by
imposing criminal sanctions on those who engage in research or chemical
analysis of the drug, DEA would prevent the future discovery of its
possible medical use.
DEA Response: DEA appreciates this comment and asserts the
following: As stated above, ethylphenidate has been placed under
international control. In order to comply with treaty obligations, DEA
must place ethylphenidate under the most appropriate schedule, taking
into consideration all appropriate scientific data. Additionally, a
qualification for placing substances in schedules II thorough IV of the
CSA is that they must have a currently accepted medical use in
treatment in the United States. Ethylphenidate has no currently
accepted medical use in treatment in the United States, lacks accepted
safety for use under medical supervision, and possesses a high
potential for abuse. Thus, DEA asserts that the placement of
ethylphenidate in schedule I of the CSA is warranted. With respect to
research, the placement of substances in schedule I of the CSA does not
preclude research into this substance. DEA registrants wishing to
conduct research on schedule I substances, including ethylphenidate,
may apply for permission to do so through the schedule I researcher
registration program.
DEA received a comment expressing that ethylphenidate should be
categorized as a schedule II drug ``until further research has been
conducted to prove its viability.''
DEA Response: DEA appreciates this comment and asserts the
following: According to the CSA, schedule I substances are defined as
drugs that have no known medical use in treatment in the United States,
and have a high potential for abuse. Additionally, according to the
CSA, schedule II substances also have a high potential for abuse but
have a currently accepted medical use in treatment. Accordingly, DEA
proposed to place ethylphenidate in schedule I of the CSA, due to its
lack of a currently accepted medical use in treatment in the United
States, its lack of accepted safety for use under medical supervision,
and its high potential for abuse.
DEA received one comment that provided statements that were neither
explicitly for nor against the proposed rule.
In this comment, the commenter suggested that instead of creating a
new rule for the control of ethylphenidate, DEA should simply clarify
the existing rule which controlled methylphenidate. According to this
commenter, this suggested amendment would extend control to all
derivatives of methylphenidate. The commenter also expressed an
understanding of DEA's intent to schedule ethylphenidate but questioned
whether a standard notice-and-comment procedure was needed for an
action that could be addressed by clarifying existing rulemaking.
DEA Response: DEA appreciates this suggestion and asserts the
following: Ethylphenidate was placed under international control on
March 16, 2017, during the CND's 60th session. As a signatory to the
1971 Convention on Psychotropic Substances, it is incumbent upon DEA to
place ethylphenidate in its most appropriate schedule under the CSA.
Therefore, DEA proposed to place ethylphenidate in schedule I of the
CSA because it has no currently accepted medical use in treatment in
the United States, lacks accepted safety for use under medical
supervision, and has an abuse potential similar to that of
methylphenidate. As explained in the NPRM, because the procedures in 21
U.S.C. 811(d)(3) and (4) for consultation and issuance of a temporary
order for ethylphenidate were not followed, DEA utilized the procedures
for permanent scheduling set forth in 21 U.S.C. 811(a) and (b) to
control ethylphenidate, which required notice and an opportunity for
hearing.
Scheduling Conclusion
After consideration of the public comments, scientific and medical
evaluation and accompanying scheduling recommendation from HHS, and
after its own eight-factor evaluation, DEA finds that these facts and
all relevant data constitute substantial evidence of potential for
abuse of ethylphenidate. As such, DEA is permanently scheduling
ethylphenidate as a controlled substance under schedule I of the CSA.
The permanent scheduling of ethylphenidate will fulfill the United
States' obligations as a party to the 1971 Convention.
Determination of Appropriate Schedule
The CSA establishes five schedules of controlled substances known
as schedules I, II, II, IV, and V. The CSA also specifies the findings
requires to place a drug or other substance in any particular schedule,
21 U.S.C. 812(b). After consideration of the analysis and
recommendation of the Acting Assistant Secretary for Health of HHS and
review of all other available data, the Administrator of DEA, pursuant
to 21 U.S.C. 812(b)(1), finds that:
(1) Ethylphenidate has a high potential for abuse that is
comparable to other scheduled substances, such as methylphenidate (a
schedule II substance);
(2) Ethylphenidate has no currently accepted medical use in
treatment in the United States. In HHS' 2020 recommendation to
control ethylphenidate, it was noted there are no approved New Drug
Applications for ethylphenidate and no known therapeutic
applications for ethylphenidate in the United States. DEA is not
aware of any other evidence suggesting that ethylphenidate has
[[Page 84284]]
a currently accepted medical use in treatment in the United
States.\5\
---------------------------------------------------------------------------
\5\ When placing a substance in schedule I, DEA must consider
whether the substance has a currently accepted medical use in
treatment in the United States. 21 U.S.C. 812(b)(1)(B) There is no
evidence suggesting that ethylphenidate has a currently accepted
medical use in treatment in the United States. To determine whether
a drug or other substance has a currently accepted medical use, DEA
has traditionally applied a five-part test to a drug or substance
that has not been approved by the FDA: i. The drug's chemistry must
be known and reproducible; ii. there must be adequate safety
studies; iii. there must be adequate and well-controlled studies
proving efficacy; iv. the drug must be accepted by qualified
experts; and v. the scientific evidence must be widely available.
See Marijuana Scheduling Petition; Denial of Petition; Remand, 57 FR
10499 (Mar. 26, 1992), pet. for rev. denied, Alliance for Cannabis
Therapeutics v. Drug Enforcement Admin., 15 F.3d 1131, 1135 (D.C.
Cir. 1994). DEA and HHS applied the traditional five-part test for
currently accepted medical use in this matter. In a recent published
letter in a different context, HHS applied an additional two-part
test to determine currently accepted medical use for substances that
do not satisfy the five-part test: (1) whether there exists
widespread, current experience with medical use of the substance by
licensed health care practitioners operating in accordance with
implemented jurisdiction-authorized programs, where medical use is
recognized by entities that regulate the practice of medicine, and,
if so, (2) whether there exists some credible scientific support for
at least one of the medical conditions for which part (1) is
satisfied. On April 11, 2024, the Department of Justice's Office of
Legal Counsel (OLC) issued an opinion, which, among other things,
concluded that HHS's two-part test would be sufficient to establish
that a drug has a currently accepted medical use. Office of Legal
Counsel, Memorandum for Merrick B. Garland Attorney General Re:
Questions Related to the Potential Rescheduling of Marijuana at 3
(April 11, 2024). For purposes of this final rule, there is no
evidence that health care providers have widespread experience with
medical use of ethylphenidate or that the use of ethylphenidate is
recognized by entities that regulate the practice of medicine under
either the traditional five-part test or the two-part test.
---------------------------------------------------------------------------
(3) There is a lack of accepted safety for use of ethylphenidate
under medical supervision. Because ethylphenidate has no approved
medical use and has not been investigated as a new drug, its safety
for use under medical supervision has not been determined.
Based on these findings, the Administrator of DEA concludes that
ethylphenidate, as well as its salts, isomers, and salts of isomers
whenever the existence of such salts, isomers, and salts of isomers is
possible, warrants control in schedule I of the CSA.
Requirements for Handling Ethylphenidate
Ethylphenidate is subject to the CSA's schedule I regulatory
controls and administrative, civil, and criminal sanctions applicable
to the manufacture, distribution, reverse distribution, import, export,
engagement in research, conduct instructional activities or chemical
analysis with, and possession of schedule I controlled substances,
including the following:
1. Registration. Any person who handles (manufactures, distributes,
reverse distributes, imports, exports, engages in research, or conducts
instructional activities or chemical analysis with, or possesses), or
who desires to handle, ethylphenidate must register with DEA to conduct
such activities pursuant to 21 U.S.C. 822, 823, 957, and 958, and in
accordance with 21 CFR parts 1301 and 1312. Any person who currently
handles ethylphenidate and is not registered with DEA must submit an
application for registration and may not continue to handle
ethylphenidate, unless DEA has approved that application for
registration pursuant to 21 U.S.C. 822, 823, 957, 958, and in
accordance with 21 CFR parts 1301 and 1312. Retail sales of schedule I
controlled substances to the general public are not allowed under the
CSA. Possession of any quantity in a manner not authorized by the CSA
is unlawful and those in possession of any quantity may be subject to
prosecution pursuant to the CSA.
2. Disposal of stocks. Any person unwilling or unable to obtain a
schedule I registration must surrender or transfer all quantities of
currently held ethylphenidate to a person registered with DEA before
the effective date of a final scheduling action in accordance with all
applicable Federal, State, local, and tribal laws. Ethylphenidate must
be disposed of in accordance with 21 CFR part 1317, in addition to all
other applicable Federal, State, local, and tribal laws.
3. Security. Ethylphenidate is subject to schedule I security
requirements and must be handled and stored pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.71-1301.76, as of the effective date
of this final scheduling action. Non-practitioners handling
ethylphenidate must comply with the employee screening requirements of
21 CFR 1301.90-1301.93.
4. Labeling and Packaging. All labels, labeling, and packaging for
commercial containers of ethylphenidate must comply with 21 U.S.C. 825,
and be in accordance with 21 CFR part 1302.
5. Quota. Only registered manufacturers are permitted to
manufacture ethylphenidate in accordance with a quota assigned pursuant
to 21 U.S.C. 826, and in accordance with 21 CFR part 1303.
6. Inventory. Every DEA registrant who possesses any quantity of
ethylphenidate must take an inventory of ethylphenidate on hand,
pursuant to 21 U.S.C. 827 and in accordance with 21 CFR 1304.03,
1304.04, and 1304.11(a) and (d).
Any person who registers with DEA must take an initial inventory of
all stocks of controlled substances (including ethylphenidate) on hand
on the date the registrant first engages in the handling of controlled
substances, pursuant to 21 U.S.C. 827 and in accordance with 21 CFR
1304.03, 1304.04, and 1304.11(a) and (b).
After the initial inventory, every DEA registrant must take an
inventory of all controlled substances (including ethylphenidate) on
hand every two years, pursuant to 21 U.S.C. 827 and in accordance with
21 CFR 1304.03, 1304.04, and 1304.11.
7. Records and Reports. Every DEA registrant must maintain records
and submit reports for ethylphenidate, or products containing
ethylphenidate, pursuant to 21 U.S.C. 827 and in accordance with 21 CFR
1301.74(b) and (c), 1301.76(b), and parts 1304, 1312 and 1317.
Manufacturers and distributors must submit reports regarding
ethylphenidate to the Automation of Reports and Consolidated Order
System pursuant to 21 U.S.C. 827 and in accordance with 21 CFR parts
1304 and 1312.
8. Order Forms. Every DEA registrant who distributes ethylphenidate
must comply with the order form requirements, pursuant to 21 U.S.C. 828
and 21 CFR part 1305.
9. Importation and Exportation. All importation and exportation of
ethylphenidate must comply with 21 U.S.C. 952, 953, 957, and 958, and
in accordance with 21 CFR parts 1304 and 1312.
10. Liability. Any activity involving ethylphenidate not authorized
by, or in violation of, the CSA or its implementing regulations, is
unlawful, and may subject the person to administrative, civil, and/or
criminal sanctions.
Regulatory Analyses
Executive Orders 12866 (Regulatory Planning and Review), 13563
(Improving Regulation and Regulatory Review), and 14094 (Modernizing
Regulatory Review)
In accordance with 21 U.S.C. 811(a), this final scheduling action
is subject to formal rulemaking procedures performed ``on the record
after opportunity for a hearing,'' which are conducted pursuant to the
provisions of 5 U.S.C. 556 and 557. The CSA sets forth the procedures
and criteria for scheduling a drug or other substance. Such actions are
exempt from review by the Office of Management and Budget pursuant to
section 3(d)(1) of Executive Order (E.O.) 12866 and the principles
[[Page 84285]]
reaffirmed in E.O. 13563. E.O. 14094 modernizes the regulatory review
process to advance policies that promote the public interest and
address national priorities.
Executive Order 12988, Civil Justice Reform
This regulation meets the applicable standards set forth in
sections 3(a) and 3(b)(2) of E.O. 12988 to eliminate drafting errors
and ambiguity, minimize litigation, provide a clear legal standard for
affected conduct, and promote simplification and burden reduction.
Executive Order 13132, Federalism
This rulemaking does not have federalism implications warranting
the application of E.O. 13132. The proposed rule does not have
substantial direct effects on the states, on the relationship between
the national government and the states, or on the distribution of power
and responsibilities among the various levels of government.
Executive Order 13175, Consultation and Coordination With Indian Tribal
Governments
This rule does not have tribal implications warranting the
application of E.O. 13175. It does not have substantial direct effects
on one or more Indian tribes, on the relationship between the Federal
government and Indian tribes, or on the distribution of power and
responsibilities between the Federal government and Indian tribes.
Paperwork Reduction Act of 1995
This action does not impose a new collection of information
requirement under the Paperwork Reduction Act of 1995.\6\ Also, this
proposed rule would not impose new or modify existing recordkeeping or
reporting requirements on state or local governments, individuals,
businesses, or organizations. However, this proposed rule would require
compliance with the following existing OMB collections: 1117-0003,
1117-0004, 1117-0006, 1117-0008, 1117-0009, 1117-0010, 1117-0012, 1117-
0014, 1117-0021, 1117-0023, 1117-0029, and 1117-0056. An agency may not
conduct or sponsor, and a person is not required to respond to, a
collection of information unless it displays a currently valid OMB
control number.
---------------------------------------------------------------------------
\6\ 44 U.S.C. 3501-3521.
---------------------------------------------------------------------------
Regulatory Flexibility Act
The Administrator of DEA, in accordance with the Regulatory
Flexibility Act, 5 U.S.C. 601-612, has reviewed this final rule, and by
approving it, certifies that it will not have a significant economic
impact on a substantial number of small entities.
DEA is placing the substance ethylphenidate (chemical name: ethyl
2-phenyl-2-(piperidin-2-yl)acetate), including its salts, isomers, and
salts of isomers, in schedule I of the CSA to enable the United States
to meet its obligations under the 1971 Convention. This action imposes
the regulatory controls and administrative, civil, and criminal
sanctions applicable to schedule I controlled substances on persons who
handle (manufacture, distribute, reverse distribute, import, export,
engage in research, conduct instructional activities or chemical
analysis with, or possess) or propose to handle ethylphenidate.
Based on the review of HHS's scientific and medical evaluation and
all other relevant data, DEA determined that ethylphenidate has high
potential for abuse, has no currently accepted medical use in treatment
in the United States, and lacks accepted safety for use under medical
supervision. DEA's research confirms that there is no legitimate
commercial market for ethylphenidate in the United States. Therefore,
this final rule will not have a significant economic impact on a
substantial number of small entities.
Unfunded Mandates Reform Act of 1995
On the basis of information contained in the ``Regulatory
Flexibility Act'' section above, DEA has determined pursuant to the
Unfunded Mandates Reform Act (UMRA) of 1995 (2 U.S.C. 1501 et seq.)
that this final rule would not result in any Federal mandate that may
result ``in the expenditure by State, local, and tribal governments, in
the aggregate, or by the private sector, of $100,000,000 or more
(adjusted annually for inflation) in any 1 year . . . .'' Therefore,
neither a Small Government Agency Plan nor any other action is required
under UMRA of 1995.
Congressional Review Act
This rule is not a major rule as defined by the Congressional
Review Act (CRA), 5 U.S.C. 804. However, pursuant to the CRA, DEA is
submitting a copy of the final rule to both Houses of Congress and to
the Comptroller General.
List of Subjects in 21 CFR Part 1308
Administrative practice and procedure, Drug traffic control,
Reporting and recordkeeping requirements.
For the reasons set out above, 21 CFR part 1308 is amended as
follows:
PART 1308--SCHEDULES OF CONTROLLED SUBSTANCES
0
1. The authority citation for part 1308 continues to read as follows:
Authority: 21 U.S.C. 811, 812, 871(b), 956(b), unless otherwise
noted.
0
2. In Sec. 1308.11:
0
a. Redesignate paragraphs (f)(6) through (f)(12) as (f)(7) through
(f)(13); and
0
b. Add a new paragraph (f)(6)
The addition reads as follows:
Sec. 1308.11 Schedule I.
* * * * *
(f) * * *
------------------------------------------------------------------------
------------------------------------------------------------------------
* * * * * * *
(6) Ethylphenidate (ethyl 2-phenyl-2-(piperidin-2- 1727
yl)acetate)..............................................
* * * * * * *
------------------------------------------------------------------------
* * * * *
Signing Authority
This document of the Drug Enforcement Administration was signed on
October 10, 2024, by Administrator Anne Milgram. That document with the
original signature and date is maintained by DEA. For administrative
purposes only, and in compliance with requirements of the Office of the
Federal Register, the undersigned DEA Federal Register Liaison Officer
has been authorized to sign and submit the document in electronic
format for publication, as an official document of DEA. This
administrative process in no way alters the legal effect of this
document upon publication in the Federal Register.
[[Page 84286]]
Heather Achbach,
Federal Register Liaison Officer, Drug Enforcement Administration.
[FR Doc. 2024-24083 Filed 10-21-24; 8:45 am]
BILLING CODE 4410-09-P